BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 20507800)

  • 1. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection.
    Jones J; Colquitt J; Shepherd J; Harris P; Cooper K
    Health Technol Assess; 2010 May; 14 Suppl 1():23-9. PubMed ID: 20507800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entecavir for the treatment of chronic hepatitis B infection.
    Shepherd J; Gospodarevskaya E; Frampton G; Cooper K
    Health Technol Assess; 2009 Oct; 13 Suppl 3():31-6. PubMed ID: 19846026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telbivudine for the treatment of chronic hepatitis B infection.
    Hartwell D; Jones J; Harris P; Cooper K
    Health Technol Assess; 2009 Oct; 13 Suppl 3():23-30. PubMed ID: 19846025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.
    Dakin H; Sherman M; Fung S; Fidler C; Bentley A
    Pharmacoeconomics; 2011 Dec; 29(12):1075-91. PubMed ID: 22077579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
    Dakin H; Bentley A; Dusheiko G
    Value Health; 2010 Dec; 13(8):922-33. PubMed ID: 20825619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
    N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.
    Bermingham SL; Hughes R; Fenu E; Sawyer LM; Boxall E; T Kennedy P; Dusheiko G; Hill-Cawthorne G; Thomas H
    Value Health; 2015 Sep; 18(6):800-9. PubMed ID: 26409607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
    Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
    Dakin H; Fidler C; Harper C
    Value Health; 2010 Dec; 13(8):934-45. PubMed ID: 20825624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.
    Wu B; Li T; Chen H; Shen J
    Value Health; 2010 Aug; 13(5):592-600. PubMed ID: 20561341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand.
    Tantai N; Chaikledkaew U; Tanwandee T; Werayingyong P; Teerawattananon Y
    BMC Health Serv Res; 2014 Apr; 14():170. PubMed ID: 24731689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [An economic evaluation of different treatments for HBeAg-positive chronic hepatitis B in China].
    Larry L; Lu XZ; Alison T
    Zhonghua Gan Zang Bing Za Zhi; 2007 Jun; 15(6):431-6. PubMed ID: 17594808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.
    Ke W; Zhang C; Liu L; Gao Y; Yao Z; Ye X; Zhou S; Yang Y
    Hepatol Int; 2016 Nov; 10(6):924-936. PubMed ID: 27271357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis.
    Kanwal F; Gralnek IM; Martin P; Dulai GS; Farid M; Spiegel BM
    Ann Intern Med; 2005 May; 142(10):821-31. PubMed ID: 15897532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy.
    Lui YY; Tsoi KK; Wong VW; Kao JH; Hou JL; Teo EK; Mohamed R; Piratvisuth T; Han KH; Mihm U; Wong GL; Chan HL
    Antivir Ther; 2010; 15(2):145-55. PubMed ID: 20386069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.
    Veenstra DL; Sullivan SD; Clarke L; Iloeje UH; Tafesse E; Di Bisceglie A; Kowdley KV; Gish RG
    Pharmacoeconomics; 2007; 25(11):963-77. PubMed ID: 17960954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B.
    Buti M; Casado MA; Calleja JL; Salmerón J; Aguilar J; Rueda M; Esteban R
    Aliment Pharmacol Ther; 2006 Feb; 23(3):409-19. PubMed ID: 16423000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine.
    Almeida AM; da Silva AL; Cherchiglia ML; Andrade EI; de Oliveira GL; Acurcio Fde A
    Value Health; 2011; 14(5 Suppl 1):S24-8. PubMed ID: 21839893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.